[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 381-400; 401-420; 421-440; 441-460; 481-500


NICE TAs 461-480

REF

TITLE                

DHFT Formulary link 

East Midlands Cancer Network link (cancer drugs only) 

TA 461

Roflumilast for treating chronic obstructive pulmonary disease

Other agents

 
TA 462

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

 

Link to cancer network protocol

TA 463

Cabozantinib for previously treated advanced renal cell carcinoma

 

Link to cancer network protocol

TA 464

Bisphosphonates for treating osteoporosis

6.6.2 Bisphosphonates and other drugs affecting bone metabolism


TA 465

Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma

 

Link to cancer network protocol

TA 466

Baricitinib for moderate to severe rheumatoid arthritis

10.1.3 Drugs which suppress the rheumatic disease process

 
TA 467

Holoclar for treating limbal stem cell deficiency after eye burns

   
TA 468

Methylnaltrexone bromide for treating opioid-induced constipation(terminated appraisa

Not recommended by NICE

 N/A

TA 469

Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)

Not recommended by NICE

  N/A

TA 470

Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)

 Not recommended by NICE

   N/A

TA 471

Eluxadoline for treating irritable bowel syndrome with diarrhoea

   
TA 472

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab

 

Available via the CDF

TA 473

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck


Link to cancer network protocol

TA 474 

Sorafenib for treating advanced hepatocellular carcinoma

 

Link to cancer network protocol

TA 475

Dimethyl fumarate for treating moderate to severe plaque psoriasis

   
TA 476 

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

   
TA 477

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee

   
TA 478

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

 

Link to cancer network protocol

TA 479

Reslizumab for treating severe eosinophilic asthma

Only available via regional centres

 
TA 480

Tofacitinib for moderate to severe rheumatoid arthritis 

10.1.2-10.1.4 Corticosteroids, rheumatic disease suppressants, gout